Integra Therapeutics ha compartido esto
Proud to have Integra Therapeutics among the 16 companies selected for the EIC Corporate Partnership Programme — and to have had the chance to pitch FiCAT directly to teams from AstraZeneca, Bayer, Chiesi, and beyond. This is exactly the kind of bridge between deep tech and industry that accelerates the path to patients. Grateful to the EIC - European Innovation Council for making it happen. 🙏
Bringing breakthrough science closer to patients across Europe 🔬 Following weeks of tailored preparation, the EIC Corporate Partnership Programme brought 16 EIC-backed start-ups and SMEs from 9 countries together with senior decision-makers from AstraZeneca, BioVentureHub, Bayer, Bayer Co.Lab, Chiesi Group, and Coloplast during the EIC Summit 2026 in Brussels. The EIC-backed start-ups addressed the specific innovation priorities set by each corporate partner, spanning next-generation therapeutics and drug discovery technologies, transformative drug development and AI-enabled discovery, chronic respiratory disease and neonatal care, and non-pharmacological solutions for bowel, bladder and stoma care. The EIC will continue to support both the start-ups and the corporate partners over the coming six months, helping to turn these discussions into scoped pilots and commercial agreements. 🤝 Meet the EIC-backed innovators who took part: Aindo | BestHealth4U | Biomodics ApS | BiopSense Oy | ELEM Biotech | EVERSENS SL | iktos | InnoCon Medical | Integra Therapeutics | Lincbiotech | Neovivum | Qubit Pharmaceuticals | Scienta | Sequentia Biotech | Preemie | Trince 🎥 Watch the highlights: https://lnkd.in/gywvPHMp #eicBAS #EICSummit26